Program
sotatercept
Also written as “Sotatercept”, “Sotatercept 0.3 mg/kg” and “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”.
Its studies are mostly in Pulmonary Arterial Hypertension · Anemia · Hypertension, Pulmonary · Multiple Myeloma · beta-Thalassemia, led by 2 companies.
Drug pageSotatercept: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 228 open or running | phase 4since May 15, 2026 | May 22, 2009 | Mar 21, 2028phase 4 · NCT07899905 |
| Bristol-Myers Squibb | 40 open or running | phase 2since Sep 3, 2008 | Sep 3, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 3, 2008First study: phase 2 study in Multiple MyelomaFirst studyNCT00747123 · 30 enrolled · Russian Federation
- Jun 16, 2010Phase 2 study in AnemiaNCT01146574 · 50 enrolled · United States
- Apr 3, 2012Phase 2 study in beta-ThalassemiaNCT01571635 · 46 enrolled · France, Greece, Italy and more
- Nov 26, 2013Phase 2 study in AnemiaNCT01999582 · 50 enrolled · Belgium, Germany, Portugal and more
TargetBeta
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule
Other programs on INHBA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| garetosmabrule | Regeneron Pharmaceuticals | phase 3 | 9 |
Studies
All 4 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01999582Anemia · Belgium, Germany, Portugal and more | 2 | Completed | Aug 31, 2016 | 50 |
| NCT01571635beta-Thalassemia · France, Greece, Italy and more | 2 | Terminated | Jul 2, 2015 | 46 |
| NCT01146574Anemia · United States | 2 | Completed | Mar 7, 2016 | 50 |
| NCT00747123Multiple Myeloma · Russian Federation | 2 | Completed | Aug 1, 2009 | 30 |
How it is read
Names in the registry
- “Sotatercept”, 22 entries
- “Sotatercept 0.3 mg/kg”, 1 entry
- “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”, 1 entry
- “Sotatercept Autoinjector”, 1 entry
- “ACE-011”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 12 studies
- Anemia, 5 studies
- Hypertension, Pulmonary, 4 studies
- Multiple Myeloma, 1 study
- beta-Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.